English

Revenio Group Corporation: Managers' transactions

Report this content

Revenio Group Corporation, Managers' transactions, May 31, 2017 at 15:30

Revenio Group Corporation: Managers' transactions

Person subject to the notification requirement
Name:Pulkkinen, Robin 
Position:Chief Financial Officer
   
Initial Notification 
Reference number:743700I27E0FWSXLKK04_20170524134755_2
   
Issuer
Name:Revenio Group Oyj
LEI:743700I27E0FWSXLKK04
   
Transaction details
Transaction date:2017-05-30
Nature of the transaction:Acceptance of a Stock Option
Further details: 
 Linked to stock option programme
 
Instrument:Financial Instrument Linked to a Share or a Debt Instrument
ISIN:FI4000261037
 
Volume:5000
Unit price: 
 
Aggregated transactions
Volume:5000
Volume weighted average price: 

For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932

Distribution:
Nasdaq Helsinki 
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki.